|Bid||7.78 x 1000|
|Ask||7.81 x 900|
|Day's Range||7.71 - 7.97|
|52 Week Range||7.71 - 20.05|
|Beta (5Y Monthly)||3.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.36|
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ: PRVB). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.The investigation concerns whether Provention and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining ...
NEW YORK, NY / ACCESSWIRE / April 15, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Provention Bio, Inc. ("Provention" or the "Company") (NASDAQ:PRVB).
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.